公开(公告)号：EP4331587A1

公开(公告)日：2024-03-06

申请号：EP22796144.8

申请日：2022-04-27

申请人： Oncocross Co., Ltd. ,  Jeil Pharmaceutical Co., Ltd.

发明人： KIM, Yi Rang ,  PARK, Sang Yun ,  YANG, Ga Eul

IPC分类号： A61K31/5377 ,  A61P3/00 ,  A61P3/04 ,  A61P1/16 ,  A61P35/00

摘要： The present invention relates to a composition for preventing or treating metabolic diseases, containing 10-ethoxy-8-(morpholinomethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a salt hydrate thereof as an active ingredient. Due to an adipocyte differentiation inhibitory effect, a fat accumulation inhibitory effect, an NAFLD inhibitory effect, and an NASH-induced fibrosis inhibitory effect of the composition, it is possible to prevent or treat metabolic diseases including nonalcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, nonalcoholic fatty liver (NAFL), and NAFLD-associated liver fibrosis, fatty liver, and obesity.